Inotrem Announces Positive Outcome of its Phase II ASTONISH Trial in Septic Shock Patients Demonstra
ASTONISH confirms the therapeutic potential of nangibotide in septic shock patients with excessive activation of the TREM-1 pathwayASTONISH confirms that the soluble TREM-1 biomarker predicts response to nangibotide treatmentPARIS--(BUSINESS WIRE)--#biotech--Inotrem, an advanced clinical stage biotech company specia...
Source: pharmiweb.com